Biology of tumor necrosis factor-alpha- implications for psoriasis.

作者: Arndt J. G. Schottelius , Lyle L. Moldawer , Charles A. Dinarello , Khusru Asadullah , Wolfram Sterry

DOI: 10.1111/J.0906-6705.2004.00205.X

关键词: Receptor expressionRegulation of gene expressionMedicineImmunologyImmunotherapySignal transductionProinflammatory cytokineCytokineTumor necrosis factor alphaPsoriasis

摘要: Numerous recent investigations have pointed to a key role of the proinflammatory, pleiotropic cytokine tumor necrosis factor-alpha (TNF-alpha) in host defense and inflammatory processes. TNF overexpression has been found lesional skin circulation psoriatic patients, it was suggested that TNF-alpha is crucial this other immune diseases. Several approaches inhibit activity developed. These include three different neutralizing antibodies as well soluble receptors with characteristic properties designed bind 17-KDa trimeric 26-KDa membrane-bound form TNF-alpha. Clinical trials demonstrated significant antipsoriatic effects, likely blocking will become an important therapeutic option. The data available from these contribute further understanding disease by demonstrating major An in-depth regulation gene expression, protein production, receptor signaling pathways may lead further, potentially novel strategies active small molecules, suitable for oral application future. Here we review current knowledge biology, activity, their clinical immunological effects psoriasis. In addition, host-defense chronic TNF-blocking are discussed.

参考文章(145)
P Mease, Psoriatic arthritis: the role of TNF inhibition and the effect of its inhibition with etanercept. Clinical and Experimental Rheumatology. ,vol. 20, pp. 116- 121 ,(2002)
Young J, Newman Nb, Poiesz Bj, Zamkoff Kw, Rudolph Ar, A phase I trial of subcutaneously administered recombination tumor necrosis factor to patients with advanced malignancy. Journal of biological response modifiers. ,vol. 8, pp. 539- ,(1989)
Smolen J, Witzmann G, Studnicka-Benke A, Höfler E, Steiner G, Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis. The Journal of Rheumatology. ,vol. 22, pp. 406- 412 ,(1995)
M. Ponteggia, E. Patucchi, Stefano Coaccioli, Adolfo Puxeddu, C. Pizzuti, D. Marioli, L. Di Cato, Impaired cutaneous cell-mediated immunity in newly diagnosed rheumatoid arthritis. Panminerva Medica. ,vol. 42, pp. 263- 266 ,(2000)
Brett Giroir, Véronique Kruys, Bruce Beutler, Junyan Han, Tumor Necrosis Factor: The molecules and Their Emerging Role in Medicine Bruce Beutler. ,(1992)
Georgopoulos S, Kollias G, Plows D, Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice Journal of Inflammation. ,vol. 46, pp. 86- 97 ,(1996)
B F Leeb, H Bröll, G Partsch, A Dunky, J S Smolen, G Steiner, Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid The Journal of Rheumatology. ,vol. 24, pp. 518- 523 ,(1997)
B. J. Nickoloff, S. L. Kunkel, G. D. Karabin, J. T. Elder, J. N. W. N. Barker, R. S. Mitra, V. M. Dixit, V. M. Dixit, C. E. M. Griffiths, V. Sarma, Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. American Journal of Pathology. ,vol. 138, pp. 129- 140 ,(1991)
A. M. Bendele, L. W. Moreland, D. P. Mccabe, J. R. Caldwell, J.-M. Dayer, J. E. Seely, S. W. Martin, J. L. Frazier, S. A. Lyons, C. L. Yee, G. Henry, M. Sack, A. M. Cohen, M. E. Cosenza, C. K. Edwards, T. Kohno, M. Weisman, Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis. The Journal of Rheumatology. ,vol. 27, pp. 601- 609 ,(2000)
S A Haas-Smith, D Hicks, C Ritchlin, R J Looney, J Cappuccio, C K Osterland, Patterns of cytokine production in psoriatic synovium. The Journal of Rheumatology. ,vol. 25, pp. 1544- 1552 ,(1998)